HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.

AbstractBACKGROUND:
The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy.
METHODS:
We analyzed data from a prospective, multicenter observational study to determine the frequency and risk factors for VTE in ambulatory cancer patients initiating a new chemotherapy regimen. The association of VTE with clinical variables was characterized using univariate and multivariate analysis.
RESULTS:
Among 3003 patients treated with at least one cycle of chemotherapy, VTE occurred in 58 (1.93%) over a median follow-up of 2.4 months (0.8%/mo). The incidence varied significantly by site of cancer (P = 0.01) with highest rates in upper gastrointestinal (2.3%/mo) and lung cancer (1.2%/mo), and lymphoma (1.1%/mo). An elevated prechemotherapy platelet count was significantly associated with an increased rate of VTE (P for trend = 0.005). The incidence of VTE was 3.98% (1.66%/mo) for patients with a prechemotherapy platelet count > or = 350,000, compared with 1.25% (0.52%/mo) for patients with platelet counts of < 200,000 (P for trend=0.0003). In multivariate analysis, a prechemotherapy platelet count of > or = 350,000/mm(3) (adjusted OR 2.81, 95% CI 1.63-4.93, P = 0.0002), site of cancer, hemoglobin < 10 g/dL or use of erythropoietin, and use of white cell growth factors in high-risk sites of cancer were significantly associated with VTE.
CONCLUSIONS:
Symptomatic VTE is a frequent complication of chemotherapy. The prechemotherapy platelet count is a unique risk factor and can help identify high-risk patients for future trials of thromboprophylaxis.
AuthorsAlok A Khorana, Charles W Francis, Eva Culakova, Gary H Lyman
JournalCancer (Cancer) Vol. 104 Issue 12 Pg. 2822-9 (Dec 15 2005) ISSN: 0008-543X [Print] United States
PMID16284987 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2005 American Cancer Society.
Topics
  • Age Distribution
  • Aged
  • Analysis of Variance
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Chi-Square Distribution
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Neoplasms (drug therapy, mortality, pathology)
  • Probability
  • Prognosis
  • Prospective Studies
  • Risk Factors
  • Severity of Illness Index
  • Sex Distribution
  • Survival Rate
  • Thromboembolism (chemically induced, epidemiology)
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: